STOCK TITAN
  1. Home
  2. Sec-filings
  3. IGC
  4. [S-3] IGC Pharma, Inc. Shelf Registration Statement

[S-3] IGC Pharma, Inc. Shelf Registration Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-3

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock IGC logo
IGC Pharma Inc

NYSE:IGC

IGC Rankings

#5416 Ranked by Market Cap
N/A Ranked by Dividends

IGC Latest News

Sep 2, 2025
IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada
Aug 28, 2025
IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome
Aug 27, 2025
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."
Aug 25, 2025
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
Aug 19, 2025
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

IGC Latest SEC Filings

Aug 18, 2025
[DEF 14A] IGC Pharma, Inc. Definitive Proxy Statement
Aug 4, 2025
[PRE 14A] IGC Pharma, Inc. Preliminary Proxy Statement
Jun 27, 2025
[10-K] IGC Pharma, Inc. Files Annual Report

IGC Stock Data

39.82M
83.23M
8.45%
18.55%
1.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
POTOMAC